| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/20/2000 | WO2000041727A1 Transcutaneous photodynamic treatment of targeted cells |
| 07/20/2000 | WO2000041726A2 Noninvasive vascular therapy |
| 07/20/2000 | WO2000041725A2 Therapeutic compositions for metabolic bone disorders or bone metastases |
| 07/20/2000 | WO2000041717A2 Chorionic gonadotropin dna vaccines and methods |
| 07/20/2000 | WO2000041715A1 New dialysis method |
| 07/20/2000 | WO2000041713A2 Composition and method for improving function of embryonic kidney transplants |
| 07/20/2000 | WO2000041709A1 Nasal spray based on xylometazoline and camomile extract |
| 07/20/2000 | WO2000041708A1 Composition for treating obesity and aesthetic treatment method |
| 07/20/2000 | WO2000041704A1 Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| 07/20/2000 | WO2000041703A1 Administration of an anti-endotoxin drug by intravenous infusion |
| 07/20/2000 | WO2000041702A1 External steroid preparation |
| 07/20/2000 | WO2000041701A1 Use of estrogens and delta-gonadien-21-ol-3,20-diones for treating insulin dependent and non-insulin dependent diabetes |
| 07/20/2000 | WO2000041700A1 Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders |
| 07/20/2000 | WO2000041699A1 Use of estrogens and delta-gonadien-21-ol-3,20-diones |
| 07/20/2000 | WO2000041698A1 φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| 07/20/2000 | WO2000041697A1 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia |
| 07/20/2000 | WO2000041696A1 Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances |
| 07/20/2000 | WO2000041695A1 Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia |
| 07/20/2000 | WO2000041694A2 Compositions having improved stability |
| 07/20/2000 | WO2000041693A2 Compositions having improved delivery of actives |
| 07/20/2000 | WO2000041692A2 Compositions having improved stability |
| 07/20/2000 | WO2000041691A1 Dry skin remedies |
| 07/20/2000 | WO2000041690A1 Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism |
| 07/20/2000 | WO2000041689A1 Telomerase inhibitors |
| 07/20/2000 | WO2000041688A1 Use of an amiodarone compound as antifungal agent |
| 07/20/2000 | WO2000041687A2 Composition and methods for administration of water-insoluble paclitaxel derivatives |
| 07/20/2000 | WO2000041686A1 Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins |
| 07/20/2000 | WO2000041684A1 A pharmaceutical combination for the treatment of depression |
| 07/20/2000 | WO2000041683A2 Transdermal therapeutic system with self-adhesive matrix, containing organic acid addition salts of morphine- or morphinan-type alkaloids |
| 07/20/2000 | WO2000041681A2 MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST |
| 07/20/2000 | WO2000041680A1 Pharmaceutical mixture comprising a combination of a profen and other active compounds |
| 07/20/2000 | WO2000041678A1 Methods for treating ovarian cancer, poly(phosphoester) compositions, and biodegradable articles for same |
| 07/20/2000 | WO2000041677A1 Granules for oral administration, process for producing the same, and tablets produced from the granules |
| 07/20/2000 | WO2000041675A1 Cosmetics and skin preparations for external use |
| 07/20/2000 | WO2000041670A2 Pharmaceutical forms and methods for penetration continuity |
| 07/20/2000 | WO2000041669A2 Benzimidazole vascular damaging agents |
| 07/20/2000 | WO2000041566A1 Regulation of endogenous gene expression in cells using zinc finger proteins |
| 07/20/2000 | WO2000041565A1 Method for increasing productivity in breeder hens |
| 07/20/2000 | WO2000041547A2 Methods of promoting or enhancing interleukin-12 production through administration of thalidomide |
| 07/20/2000 | WO2000041545A2 Regulators of the pct or smoothened pathway, compositions and uses related thereto |
| 07/20/2000 | WO2000041541A2 Method of isolating mucilaginous polysaccharides and uses thereof |
| 07/20/2000 | WO2000041540A2 Herbal supplement for increased muscle strength and endurance for athletes |
| 07/20/2000 | WO2000041531A2 Serine protease inhibitors |
| 07/20/2000 | WO2000041528A2 Improved controlled release compositions and method |
| 07/20/2000 | WO2000041526A2 Use of s-triazines for treating apicomplexan parasitic infections |
| 07/20/2000 | WO2000041516A2 Reagents and methods useful for detecting diseases of the breast |
| 07/20/2000 | WO2000041514A2 Conjugates of colony stimulating factors for targeting and imaging infection and inflammation |
| 07/20/2000 | WO2000041505A2 Anthranilic acid derivatives |
| 07/20/2000 | WO2000041504A2 Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides |
| 07/20/2000 | WO2000041484A2 Novel use of phospholipids of vegetable and animal origin in nutritional therapy |
| 07/20/2000 | WO2000041482A2 Oral administration of taxoid derivatives |
| 07/20/2000 | WO2000041481A2 Medicament forms having controlled release and containing active substances which easily dissolve in water |
| 07/20/2000 | WO2000041478A2 Agglomerates by crystallisation |
| 07/20/2000 | WO2000041474A2 Anti-cd3 immunotoxins and therapeutic uses therefor |
| 07/20/2000 | WO2000041473A2 Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections |
| 07/20/2000 | WO2000041472A2 Binding partners for 5-ht5-receptors for the treatment of migraine |
| 07/20/2000 | WO2000041469A2 β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS |
| 07/20/2000 | WO2000041463A2 Combination of hepatitis b vaccine with antiviral agents |
| 07/20/2000 | WO2000028999A3 Methods of treating tardive dyskinesia and other movement disorders |
| 07/20/2000 | WO2000024885A3 p53 MORPHOLINO-BASED ANTISENSE |
| 07/20/2000 | WO2000021521A3 Sertraline oral concentrate |
| 07/20/2000 | WO2000021510A3 Formulations of fexofenadine |
| 07/20/2000 | WO2000019990A3 Rar antagonists as male anti-fertility agents |
| 07/20/2000 | WO2000019985A3 New sustained release oral formulations |
| 07/20/2000 | WO2000019984A3 Coated medicament forms with controlled active substance release |
| 07/20/2000 | WO2000016758A3 Treatment of infection |
| 07/20/2000 | WO2000016732A3 ANTI-MICROBIAL-ADHESION FRACTION DERIVED FROM $i(VACCINIUM) |
| 07/20/2000 | WO2000015246A3 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
| 07/20/2000 | WO2000015203A3 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor |
| 07/20/2000 | WO2000015176A3 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| 07/20/2000 | WO2000014097A3 Novel pyranoses |
| 07/20/2000 | WO2000014064A3 Gaba uptake inhibitors having a pyrrolidine structure |
| 07/20/2000 | WO2000003709A9 Novel dna-cleaving antitumor agents |
| 07/20/2000 | WO2000002897A9 Delta cleavage products and methods based thereon |
| 07/20/2000 | WO2000002857A9 Bis-indole derivatives and their use as antiinflammatory agents |
| 07/20/2000 | WO2000001687A9 Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| 07/20/2000 | WO2000000514A9 Synthetic spiroketal pyranes as potent anti-cancer agents |
| 07/20/2000 | WO1999064048A9 Inhibitors of hiv reverse transcriptase |
| 07/20/2000 | WO1999061014A3 Compositions and methods employing r(-) fluoxetine and other active ingredients |
| 07/20/2000 | WO1999048489A9 Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders |
| 07/20/2000 | WO1999000373A8 Benzimidazole derivatives |
| 07/20/2000 | WO1997025042A8 Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x |
| 07/20/2000 | DE19901692A1 Verfahren zur Herstellung von Pellets mit einem Gehalt von bis zu 90 Gew.% eines pharmazeutischen Wirkstoffes A process for the production of pellets with a content of up to 90% of a pharmaceutical active ingredient by weight. |
| 07/20/2000 | DE19901687A1 Opioide Analgetika mit kontrollierter Wirkstofffreisetzung Opioid analgesics controlled release |
| 07/20/2000 | DE19901686A1 Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung Retarded tramadol with a storage-stable release profile and methods for their preparation |
| 07/20/2000 | DE19901683A1 Analgetikum mit kontrollierter Wirkstofffreisetzung Analgesic with controlled release of active ingredient |
| 07/20/2000 | DE19901061A1 Treatment of dysfunction of autonomous nervous system, especially vagal system of the heart, with benzenesulfonyl(thio)urea derivatives optionally with beta-receptor blocker |
| 07/20/2000 | DE19901040A1 Arzneiformen mit gesteuerter Freisetzung, enthaltend gut wasserlösliche Wirkstoffe Controlled release dosage forms containing highly water-soluble drugs |
| 07/20/2000 | DE19855704A1 Mittel zur Behandlung der Symptome der Parkinsonschen Krankheit Agents for treating the symptoms of Parkinson's disease |
| 07/20/2000 | CA2697598A1 Compounds and methods to inhibit or augment an inflammatory response |
| 07/20/2000 | CA2629496A1 Process and products of purification of anhydrosugar alcohols |
| 07/20/2000 | CA2629484A1 Process and products of purification of anhydrosugar alcohols |
| 07/20/2000 | CA2372197A1 Functionalized heterocycles as chemokine receptor modulators |
| 07/20/2000 | CA2370042A1 Regulators of the pct or smoothened pathway, compositions and uses related thereto |
| 07/20/2000 | CA2363847A1 Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins |
| 07/20/2000 | CA2361924A1 Compositions for treating frequent urination and urinary incontinence |
| 07/20/2000 | CA2360581A1 A novel method for designing protein kinase inhibitors |
| 07/20/2000 | CA2360560A1 Contrast media for angiography |
| 07/20/2000 | CA2360464A1 Human peptidases |
| 07/20/2000 | CA2360387A1 Catalytic molecules |